New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
11:45 EDTCYTK, NSR, NOW, ETFC, PBROptions with increasing implied volatility: CYTK NSR NOW ETFC PBR
News For CYTK;NSR;NOW;ETFC;PBR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
16:21 EDTNOWServiceNow sees FY14 revenues $677M-$679M, consensus $671.6M
16:20 EDTNOWServiceNow sees Q4 revenue $192M-$194M, consensus $191.4M
Subscribe for More Information
16:19 EDTNOWServiceNow reports Q3 EPS 4c, consensus 1c
Subscribe for More Information
16:00 EDTPBROptions Update; October 23, 2014
Subscribe for More Information
15:30 EDTNOWNotable companies reporting after market close
Subscribe for More Information
09:38 EDTPBRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
08:20 EDTETFCE-Trade guidance conservative, says Wells Fargo
Subscribe for More Information
October 21, 2014
16:15 EDTETFCE-Trade reports Q3 DARTs of 153,000, down 1% sequentially
Subscribe for More Information
16:14 EDTETFCE-Trade reports Q3 EPS 29c, consensus 22c
Reports Q3 revenue $440M, consensus $424.93M.
16:00 EDTPBROptions Update; October 21, 2014
Subscribe for More Information
15:30 EDTETFCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Yahoo! (YHOO), consensus 30c; ACE (ACE), consensus $2.34; Discover Financial (DFS), consensus $1.34; Pinnacle Financial (PNFP), consensus 51c; Broadcom (BRCM), consensus 84c; Intuitive Surgical (ISRG), consensus $3.80; FMC Technologies (FTI), consensus 74c; Robert Half International (RHI), consensus 58c; E-Trade (ETFC), consensus 22c; Nabors Industries (NBR), consensus 36c; Waste Connections (WCN), consensus 54c; Cubist Pharmaceuticals (CBST), consensus 4c; Sonic (SONC), consensus 34c; American Campus Communities (ACC), consensus 43c; Cree (CREE), consensus 36c; Fulton Financial (FULT), consensus 20c; Costamare (CMRE), consensus 41c; Hawaiian Holdings (HA), consensus 78c; Ethan Allen (ETH), consensus 36c; Sabra Health (SBRA), consensus 55c; Rush Enterprises (RUSHA), consensus 51c.
09:37 EDTPBRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
06:29 EDTPBRPetrobras implied volatility of 133 at upper end of index mean range
October 20, 2014
16:00 EDTPBROptions Update; October 20, 2014
Subscribe for More Information
14:33 EDTPBRPetrobras called a 'scheme' by Chanos, short recommended, Bloomberg reports
Subscribe for More Information
09:52 EDTPBRDryShips unit awarded contract extensions
Subscribe for More Information
08:04 EDTNOWServiceNow should have another beat and raise quarter, says RBC Capital
Subscribe for More Information
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
06:33 EDTETFCE-Trade upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
October 17, 2014
16:01 EDTPBROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use